在慢性病中对急性冠状动脉综合征的管理考虑因素
Matthew I Tomey1, Janice Y Chyou2
1Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, 1190 Fifth Avenue, Box 1030, New York, NY, 10029, USA. matthew.tomey@mountsinai.org.
Current cardiology reports
|March 7, 2024
概括
患有慢性病 (CKD) 的患者因管理缺陷而面临急性冠状动脉综合征 (ACS) 的更糟糕后果. 在CKD中优化ACS护理需要解决治疗方法的不充分使用和预防急性损伤.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临床医学 临床医学
背景情况:
- 患有慢性病 (CKD) 的患者在急性冠状动脉综合征 (ACS) 后更容易出现不良结果.
- 临床试验中的代表性不足和基于证据的治疗方法的使用不足加剧了ACS患者中与CKD相关的生物风险.
- 目前在CKD患者中ACS的管理策略需要进行批判性评估和优化.
研究的目的:
- 批判性地评估当代证据,关于在患有CKD的患者中ACS的管理.
- 为临床医生提供实用方法,以优化这种高风险人群中的ACS管理.
- 在ACS护理的背景下,应对CKD带来的挑战.
主要方法:
- 现有证据的叙述性审查.
- 分析更新的多社会胸痛指南.
- 评估不断发展的预测和预防急性损伤的工具.
- 评估穿皮冠状动脉干预 (PCI) 和药物治疗方面的进展.
主要成果:
- 更新的指导方针强调了各种ACS表现,这对于认出CKD患者至关重要.
- 改进的工具提高了高风险CKD患者PCI的安全性和可访问性.
- 辐射接入,PCI质量,血管内成像和药物治疗方面的进步正在改进CKD中ACS的风险效益评估.
- 关键的机会包括减少治疗方法的不充分使用,预防急性损伤,以及专门研究CKD特异性ACS管理.
结论:
- 在CKD中优化ACS管理需要解决基于证据的治疗方法的不足,并提高治疗安全性.
- 预防急性损伤对于改善ACS干预的CKD患者的治疗结果至关重要.
- 进一步的研究特别研究在CKD的背景下ACS管理是必不可少的.
相关概念视频
01:17Factors Affecting Renal Clearance: Renal Impairment
91
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
91
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
01:22Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
223
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
223
01:25Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625